Metraipolis › archive › dc_a4680ab413dd

P300/CBP inhibition with inobrodib in combination with gilteritinib and venetoclax targets leukemia stem cells in epigenetic mutant AML — Europe PMC PMID:42139346

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42139346
DOI
10.1126/sciadv.aec9305
License (as archived)
solo-consultazione
Archived
2026-11-02T07:32:53.300Z
SHA-256 of the archived text
3e447a277269d346a7d866bb6e25b8eb737278728ac47780b71093f7d7ec3ea5
Stable URL of this page
https://metraipolis.com/documento/dc_a4680ab413dd

How to cite

P300/CBP inhibition with inobrodib in combination with gilteritinib and venetoclax targets leukemia stem cells in epigenetic mutant AML — Europe PMC PMID:42139346 — Europe PMC (en), https://europepmc.org/article/MED/42139346 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_a4680ab413dd (Metraipolis archive dc_a4680ab413dd, sha256 3e447a277269d346a7d866bb6e25b8eb737278728ac47780b71093f7d7ec3ea5)
BibTeX
@misc{dca4680ab413dd,
  title = {P300/CBP inhibition with inobrodib in combination with gilteritinib and venetoclax targets leukemia stem cells in epigenetic mutant AML — Europe PMC PMID:42139346},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42139346},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_a4680ab413dd; sha256 3e447a277269d346a7d866bb6e25b8eb737278728ac47780b71093f7d7ec3ea5},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42139346. Agents can read the archived copy with the MCP tool read_document.